尊敬的各位嘉宾、各位投资者： 大家好！ 欢迎大家参加深圳北芯生命科技股份有限公司首次公开发行股票并在科创板上市的网上投资者交流会。 我谨代表北芯生命，向长期以来关注、支持北芯生命的投资者、合作伙伴以及各界朋友表示热烈的欢迎 和衷心的感谢！ 北芯生命自成立以来，始终秉持"用创新和品质改善生命健康"的使命，致力于开发为心血管疾病诊疗带 来变革的精准介入解决方案。前不久，北芯生命刚度过十周年生日，站在了全新的起点上。从扎根中国 的创新萌芽，到成长为中国高性能医疗器械出海的新生代领军力量，我们始终以临床和患者为中心，坚 持产品创新与极致品质，目前已经围绕冠状动脉疾病、外周血管疾病、房颤等领域建立了核心研发技术 平台，并推出了一系列自主研发的心血管智能化精准介入解决方案。 北芯和北芯人，通过满腔热情和日夜兼程，已填补中国医疗器械产业领域中技术壁垒最高、产业链条最 长的高性能心血管精准介入器械板块的空白。此次在科创板上市，通过上市募集资金，公司将进一步加 大在创新研发和产业化上的投入，进一步丰富在研产品管线数量和扩大产能。通过持续不断地做出有临 床价值的技术突破和创新产品，我们将继续为海内外患者和临床工作者提供更精准、更 ...

Core Mission - The company aims to transform scientific research into practical technology to benefit patients, focusing on innovative high-performance medical devices [1] - The mission is to improve life and health through innovation and quality, specifically targeting cardiovascular disease intervention [1] Product Development - The company has developed a comprehensive solution for precise intervention in coronary heart disease, including the FFR system and IVUS system [1] - The FFR pressure microcatheter, launched in 2020, is the first domestically approved product in China for measuring blood flow reserve, filling a significant gap in the market [4] - The IVUS system is the first domestically developed 60MHz high-definition product approved by the National Medical Products Administration, rapidly gaining market share since its launch in 2022 [5] Market Impact - The FFR product achieved a market share of 30.6% in the coronary artery direct measurement market within a year of its launch, with applications in approximately 1,000 hospitals globally [4] - The IVUS system has also been adopted in around 1,000 hospitals, becoming the leading domestic product in its category [5] Innovation and Technology - The company has established four core technology platforms, including micro-nano device development and high-performance medical hardware development [6] - It has developed nearly 20 products and ongoing projects, positioning itself as a "small giant" in the cardiovascular intervention sector with international influence [6] Recognition and Achievements - The company has applied for over 360 patents, with more than 180 granted, including over 80 invention patents [6] - It has received various accolades, including the "National Specialized and Innovative 'Small Giant' Enterprise" certification and the Shenzhen Science and Technology Progress Award for its FFR system [6]

Core Insights - The National Medical Products Administration of China emphasizes support for high-end medical device innovation, particularly in advanced medical imaging equipment, to address the growing global demand for cardiovascular disease treatment solutions [1] - Beixin Life, a domestic company focused on high-end medical device innovation, aims to develop high-performance interventional medical devices to tackle the significant public health issue of cardiovascular diseases [1][3] - The company has successfully developed and commercialized proprietary high-performance diagnostic equipment, contributing to the advancement of domestic high-end medical devices [1][3] Industry Overview - Coronary heart disease is recognized as a major health threat globally, with cardiovascular diseases being the leading cause of death in China [2] - China has the highest annual volume of percutaneous coronary intervention (PCI) procedures, with a trend towards precision treatment guided by advanced coronary functional and imaging technologies [2] - The reliance on imported devices and materials has historically dominated the market due to high R&D barriers and long return cycles [2] Company Achievements - Since its establishment in 2015, Beixin Life has developed a series of intelligent cardiovascular interventional solutions, including the first domestically approved IVUS and FFR systems [3][4] - The company has obtained over 20 Class III medical device registrations and successfully launched 11 products [3] - Beixin Life is the only domestic company with the technology to develop and manufacture 60MHz high-frequency micro-ultrasound transducers and MEMS pressure sensor modules [4] Market Potential - The cardiovascular device market is the second largest globally and is expected to grow rapidly over the next decade, with a significant patient population for coronary heart disease [7] - The number of PCI procedures in China is projected to increase from 1.906 million in 2024 to 4.298 million by 2030, with a compound annual growth rate of approximately 14.5% [7] - The precision PCI market in China is expected to grow from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, with a compound annual growth rate exceeding 20% [7] Competitive Position - Beixin Life's FFR product captured 30.6% of the domestic market share shortly after its launch, while its IVUS product became the leading domestic option, reducing reliance on imports [8] - The company has successfully expanded its products to international markets, receiving positive feedback and achieving routine clinical use in multiple countries [8] - Beixin Life aims to enhance the synergy of its product system and adapt to international markets, thereby improving the global competitiveness of China's high-performance medical device industry [9]

Core Viewpoint - North Chip Life Technology Co., Ltd. is preparing for its IPO on the Sci-Tech Innovation Board, focusing on innovative medical devices in the cardiovascular precision intervention field [1] Company Overview - Established in 2015, North Chip Life specializes in high-performance active interventional devices for major diseases such as coronary heart disease and atrial fibrillation [1] - The company has developed key technologies, including the first domestically developed FFR system and a 60MHz high-speed IVUS system, breaking foreign monopolies [1] - Over ten products have been commercialized, with FFR and IVUS systems used in approximately 1,000 hospitals globally [1] Research and Development - North Chip Life has significantly increased R&D investment, establishing four technical platforms covering the entire chain from core sensor packaging to image analysis algorithms [1] - The company has applied for over 360 patents, with more than 180 granted, including over 80 invention patents and 14 PCT international patent applications [2] Financial Performance - Revenue figures for 2022, 2023, and 2024 are approximately 0.92 billion, 1.84 billion, and 3.17 billion respectively, with positive operating cash flow and narrowing losses [2] - Sales and management expense ratios are projected to decrease by about 21 percentage points and 26 percentage points respectively in 2024, indicating improved operational efficiency [2] Market Potential - The number of PCI procedures in China reached 1.636 million in 2023, expected to grow to 4.3 million by 2030, driving demand for the company's core products [3] - The precision PCI market in China is projected to grow from 2.04 billion in 2022 to 9.42 billion by 2030, with a compound annual growth rate exceeding 20% [3] Global Expansion - North Chip Life is the first domestic company to obtain EU CE/MDR certification for both FFR and IVUS products, with regular supply to countries like Germany, the UK, and Italy [2] - In 2024, overseas revenue reached approximately 38.83 million, a year-on-year increase of nearly 160% [2] Vision and Future Plans - The company aims to become a world-class medical technology enterprise with a long-lasting impact, focusing on technology accumulation, product matrix, and global layout [3] - With a solid R&D capability and high-performance product matrix, North Chip Life is positioned to become a representative enterprise in the high-end medical device sector in China [3]